SCHEDULE 13G/A: Brandes Investment Partners Amends Grifols SA Class B Share Ownership to 16.43%

Brandes Investment Partners, L.P. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 16.43% of Grifols SA's Class B shares as of March 31, 2025.

Summary

• Brandes Investment Partners, L.P., a Delaware-based investment adviser, has filed an Amendment No. 3 to its Schedule 13G regarding its beneficial ownership in Grifols SA.
• The filing indicates that Brandes Investment Partners, L.P. beneficially owns a total of 42,939,942 Class B shares of Grifols SA, comprising 18,761,824 Ordinary Shares (ORDs) and 24,178,118 American Depositary Receipts (ADRs).
• This aggregate amount represents 16.43% of Grifols SA's Class B shares.
• Brandes Investment Partners, L.P. holds shared dispositive power over all these shares but has no sole or shared voting power.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Grifols SA.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational news, only a statement of an investment position.

Future Outlook

This document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Grifols SA's future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a standard disclosure of a significant ownership stake by an investment firm in a publicly traded company within the biotechnology and pharmaceutical sector. It reflects an investment position rather than operational or strategic industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and liquidity.
• Investment Professionals: Offers insight into the holdings of a major investment firm, potentially informing their own investment decisions.

Key Dates

Keywords

Grifols SA, Brandes Investment Partners, Schedule 13G, Beneficial Ownership, Class B shares, SEC Filing, Investment Adviser, GRFS, Biotechnology, Pharmaceuticals